ArticleIndian journal of ophthalmology2026
Impact of intraoperative 3 mg triamcinolone acetonide injection on visual rehabilitation and inflammation control in uveitic cataract patients undergoing small-incision cataract surgery.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe study assesses the effectiveness and safety of low-dose (3 mg) intraoperative intravitreal triamcinolone acetonide (IVTA) in managing postoperative inflammation and promoting early visual rehabilitation in patients with uveitic cataracts.
methodsThis was a prospective, interventional, and comparative study that included a total of 30 patients with uveitic cataracts, who were divided into two groups. A control group that did not receive the IVTA injection and an IVTA group that received the intravitreal injection at the end of surgery. Results were monitored over 12 months. The evaluated outcomes comprised best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), anterior chamber inflammatory response, endothelial cell count (ECC), and any postoperative adverse events.
resultsAt 12 months, the IVTA group demonstrated a marked improvement in mean logMAR BCVA from 1.74 ± 0.42 to 0.27 ± 0.17, compared with 0.52 ± 0.19 in controls ( P < 0.05). Anterior chamber inflammation was better controlled in the IVTA group, although the difference was not statistically significant ( P > 0.05). No significant intergroup differences were noted in IOP or ECC. At 3 months, mean CMT measured 250.42 ± 32.41 µm in the IVTA group versus 258.25 ± 43.06 µm in controls ( P = 0.494). Postoperative complications were fewer in the IVTA group, with posterior capsule opacification (PCO) being the most frequent.
conclusionAbout 3 mg triamcinolone acetonide (TA) is not only effective but also safe in reducing postoperative inflammation and promoting early visual recovery in uveitic cataract patients undergoing surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.